<DOC>
	<DOC>NCT01919164</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial of AS902330 administered intra-articularly in subjects with primary osteoarthritis of the knee and Kellgren-Lawrence Grade 2 or 3. The trial is intended to investigate the efficacy and safety of different intra articular dosages of AS902330 (Sprifermin) in these individuals.</brief_summary>
	<brief_title>A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin (AS902330) in Patients With Osteoarthritis of the Knee</brief_title>
	<detailed_description>Subjects will be equally randomized to either one of 4 treatment arms or a placebo arm. The trial consists of a Screening period lasting up to 42 days, a two-year double-blind placebo-controlled (DBPC) treatment phase, which begins at randomization (Week 0) and ends at Year 2, and a 3-year extended follow-up phase.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Age from 40 to 85 years; of either sex Primary femorotibial osteoarthritis according to American College of Rheumatology (ACR) clinical and radiographic criteria , and meeting protocolspecified Xray criteria in the target knee at screening Pain score in the target knee and/or the need for regular symptomatic treatment of knee pain with paracetamol (acetaminophen), systemic nonsteroidal antiinflammatory drugs (NSAIDs) including cyclooxygenase (COX)2 selective inhibitors (coxibs), or tramadol on most days in the previous month (that is, more than half of the days in the previous month) A history of pain due to Osteoarthritis in the target knee for at least 6 months A protocolspecified pain score for the target knee in response to Question 1 of the WOMAC pain index ("how much pain have you had [in the target knee, over the past 48 hours] when walking on a flat surface?") after washout of at least 5 halflives of analgesic medication(s): acetaminophen, topical or oral NSAIDS, coxibs, opioids, and/or tramadol Women of childbearing potential must use a form of contraception with a failure rate of less than 1 percent per year throughout the trial Malalignment of greater than 5 degrees in the femorotibial axis of the target knee Clinical signs of inflammation (redness) in the target knee Intraarticular administration of corticosteroids or hyaluronic acid into either knee within 6 months before Screening Planned knee surgery (affecting either the target or the contralateral knee) within the next two years Concomitant conditions or treatments deemed to be incompatible with trial participation Any contraindication to MRI according to MRI guidelines, including the inability to undergo a knee MRI exam because of inability to fit in the scanner or knee coil Pregnancy or breastfeeding Participation in another clinical trial within the 30 days (or 5 halflives of the investigated compound, whichever is longer) before screening Legal incapacity or limited legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Osteoarthritis of knee</keyword>
	<keyword>AS902330</keyword>
	<keyword>Recombinant Human Fibroblast Growth Factor-18 (rhFGF-18)</keyword>
	<keyword>Sprifermin</keyword>
	<keyword>Placebo</keyword>
</DOC>